Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-01

Study Completion Date

2028-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

NCT03117036

Lymphoma, Non-Hodgkin Lymphoma, Hodgkin

RECRUITING

Samsung Medical Center-Lymphoma Cohort Study

NCT00822731

Lymphoma

COMPLETED NA

Samsung Medical Center-Lymphoma Cohort Study-II

NCT01877109

Lymphoma

COMPLETED

Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study

NCT02691351

Non-Hodgkin T-cell Lymphoma

COMPLETED

Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)

NCT01054781

Diffuse Large B-cell Lymphoma (DLBCL)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows.

1. Registration after informed consent.
2. Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood
3. Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood
4. Regular monitoring disease status and update of survival status
5. Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immunochemotherapy

Systemic chemotherapy with curative intent

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Supportive treatment

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
2. 20 years
3. Patients requiring systemic chemotherapy with curative intent
4. Written informed consent